Equities research analysts at StockNews.com began coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Free Report) in a research note issued to investors on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Nabriva Therapeutics Stock Performance
Nabriva Therapeutics has a 12 month low of $1.22 and a 12 month high of $8.45. The business has a fifty day simple moving average of $0.14. The company has a current ratio of 0.85, a quick ratio of 0.52 and a debt-to-equity ratio of 0.12. The stock has a market cap of $45.46 million, a price-to-earnings ratio of -0.07 and a beta of 1.53.
About Nabriva Therapeutics
See Also
- Five stocks we like better than Nabriva Therapeutics
- Upcoming IPO Stock Lockup Period, Explained
- 3 Stocks Leading the U.S. Agriculture Comeback
- How Technical Indicators Can Help You Find Oversold StocksĀ
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Transportation Stocks Investing
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.